机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, School of Medicine, Tongji University, Shanghai, China[2]Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, Shanghai, China[3]Department of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院肿瘤免疫科临床科室[4]Department of Respiratory and Critical Care Medicine, The First Afliated Hospital of Wenzhou Medical University, Wenzhou, China[5]Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
Background Despite the remarkable clinical advance of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer,
there are limited studies focused on evaluating efcacy of ICIs for patients with human epidermal growth factor receptor 2
(HER2)-mutant lung adenocarcinoma.
Methods We conducted a multicenter retrospective study of patients with HER2-mutant lung adenocarcinoma who received
ICIs therapy at Shanghai Pulmonary Hospital, Shanghai Chest Hospital and the First Afliated Hospital of Wenzhou Medical University between 2016 and 2021. Response was defned with reference to the Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.1.
Results Among the 26 patients enrolled in our study, the overall objective response rate (ORR) was 38.5%, disease control
rate (DCR) was 84.6% and median progression-free survival (PFS) was 7.4 months. Majority of patients were treated with
immunochemotherapy combination regimens (16/26, 61.5%), with a median PFS of 8.4 months. Among the 9 patients
receiving ICIs-based therapy as frst-line treatment, 5 patients had partial response (PR) and 4 patients had stable disease
(SD), with a median PFS of 9.1 months. Of the entire cohort, 5 patients who received ICIs before epidermal growth factor
receptor (EGFR)/HER2-targeting drugs achieved a median PFS of 8.4 months.
Conclusion Our retrospective study provides clinical evidence that front line of ICIs-based therapy is also worth considering
for the treatment to improve survival outcomes of patients with HER2-mutant lung adenocarcinoma.
基金：
This work was supported by the National Natural Science
Foundation of China (grant number: 82072568, 81874036), Shanghai
Hospital Development Center (grant number: SHDC12020110) and
Shanghai Anticancer Association (grant number: SACA-CY19B06)
第一作者机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, School of Medicine, Tongji University, Shanghai, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Xiangling Chu,Huiping Qiang,Mengqing Xie,et al.Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(10):S1020-S1020.
APA：
Xiangling Chu,Huiping Qiang,Mengqing Xie,Xing Li,Jing Zhao...&Chunxia Su.(2021).Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors.JOURNAL OF THORACIC ONCOLOGY,16,(10)
MLA：
Xiangling Chu,et al."Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors".JOURNAL OF THORACIC ONCOLOGY 16..10(2021):S1020-S1020
医学